JZJ(SH:605266)2021-10-29 16:00Financial Performance - The company's operating revenue for Q3 2021 was ¥1,287,176,980.78, representing a year-on-year increase of 19.45%[7]. - The net profit attributable to shareholders for Q3 2021 was ¥73,805,078.32, an increase of 23.20% compared to the same period last year[7]. - The net profit after deducting non-recurring gains and losses for Q3 2021 was ¥70,374,038.14, reflecting an 18.45% increase year-on-year[7]. - The comprehensive gross profit margin for the first nine months of 2021 was 35.34%, up from 33.00% in the same period last year, indicating effective category strategy implementation[13]. - The net profit for the first nine months of 2021, after deducting non-recurring gains and losses, grew by 19.28%, outpacing the overall net profit growth of 14.73%[16]. - For the first nine months of 2021, the company's operating revenue increased by 15.07%, and the comprehensive gross profit margin rose by 2.34%[45]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, grew by 19.28% due to factors such as policy support and the controlled pandemic situation[45]. - The company reported a total revenue of approximately 3.67 billion yuan and a gross profit margin of 35.34% for the first nine months of 2021, reflecting a 2.34% increase in gross profit margin year-on-year[44]. Assets and Liabilities - The company's total assets at the end of Q3 2021 reached ¥4,809,088,271.89, a 38.65% increase from the end of the previous year[11]. - Total assets increased by 38.65% primarily due to the implementation of new leasing standards[21]. - As of September 30, 2021, the company's total assets amounted to RMB 4.81 billion, an increase from RMB 3.47 billion at the end of 2020[71]. - The company's total liabilities reached RMB 3.02 billion, compared to RMB 1.77 billion at the end of 2020[74]. - The company's current assets totaled RMB 2.55 billion, down from RMB 2.79 billion at the end of 2020[71]. - The total liabilities were CNY 2,566,000,000.00, which indicates a significant leverage position for the company[90]. Cash Flow - The company reported a net cash flow from operating activities of ¥548,148,854.08 for the year-to-date, showing a significant increase of 288.75%[11]. - Cash flow from operating activities surged by 288.75% as a result of the new leasing standards affecting the classification of cash outflows[21]. - Operating cash inflow totaled CNY 3,660,855,266.91, an increase from CNY 3,174,250,886.10 in the previous period, representing a growth of approximately 15.3%[86]. - Net cash flow from operating activities reached CNY 548,148,854.08, significantly up from CNY 141,002,516.33, indicating a year-over-year increase of about 288.5%[86]. - Cash inflow from investment activities amounted to CNY 1,376,155,965.62, compared to CNY 205,417,998.58 in the prior period, marking a substantial increase of approximately 572.5%[86]. - Cash outflow for investment activities was CNY 1,843,371,062.28, up from CNY 307,349,340.07, reflecting an increase of around 499.5%[86]. - The ending balance of cash and cash equivalents was CNY 902,972,943.04, down from CNY 1,371,229,319.21, indicating a decrease of approximately 34.3%[88]. Store Expansion and Operations - The company added 590 new stores in the first nine months of 2021, including 418 self-built and 172 acquired stores, resulting in a net increase of 557 stores, bringing the total to 2,687 stores[34]. - The company achieved a 26.15% increase in total store count compared to the end of 2020, with a 27.95% increase in the Sichuan-Chongqing-Guangxi region[36]. - The company closed 33 stores due to adjustments in development planning and operational strategies, resulting in a net increase of 557 stores overall[34]. - The company plans to continue its dual strategy of self-building and acquisitions to expand its store network, particularly in underdeveloped areas[31]. - The company is focusing on expanding its sales network and enhancing online and offline service capabilities to meet rising consumer health demands[12]. Investments and Acquisitions - The company completed 8 acquisition projects in the first nine months of 2021, including 7 in Yunnan province and 1 in Guangxi, enhancing competitiveness in weak markets[31]. - In the first nine months of 2021, the company completed 8 acquisitions involving 172 stores, with a total acquisition amount of RMB 221.12 million[60]. - In Q3 2021, the company executed 4 industry acquisitions involving 94 stores, with a total acquisition amount of RMB 113.24 million[61]. - The company acquired 100% equity of Yunnan Jindanlu Pharmaceutical Co., Ltd. for RMB 23.26 million, involving 14 stores, completed on August 30, 2021[61]. - The company also acquired 100% equity of Tonghai Fuyuantang Pharmaceutical Co., Ltd. for RMB 24.83 million, involving 21 stores, completed on September 1, 2021[61]. - The company completed an asset acquisition of 29 pharmacies from Lincong Yongshengtang for RMB 26.30 million[65]. Revenue Sources and Product Performance - The revenue from pharmaceutical retail reached approximately 3.20 billion yuan, with a gross profit margin of 34.23%, representing a year-on-year increase of 1.74%[42]. - The company's self-operated platform revenue reached RMB 195.37 million, a 104.07% increase year-on-year, while third-party e-commerce platform revenue grew by 126.79%[55]. - The total online channel revenue amounted to RMB 559.67 million, reflecting a growth of 118.30% and accounting for 15.26% of total revenue[55]. - The company's revenue from providing professional services to pharmaceutical and convenience suppliers increased to 5.56% of total revenue, reflecting a recovery in business operations[44]. - Sales of medical devices decreased by 10.49%, with a sales proportion drop of 2.95%, while the gross profit margin improved by 5.03%[53]. - The sales of traditional Chinese and Western medicine increased by 17.92%, with a sales proportion increase of 2.88% and a gross profit margin recovery of 1.46%[54]. - The sales of health food and personal care products saw year-on-year increases of 21.37% and 16.29%, respectively, contributing to improved gross profit margins[54]. Financial Strategy and Future Plans - The company plans to distribute profits by increasing capital reserves, issuing 15,900,000 shares to all shareholders, and implementing an equity incentive plan[12]. - The company plans to issue up to 6,813,757 shares, raising no more than RMB 420 million to enhance regional competitiveness and logistics efficiency[66]. - The company is focusing on integrating acquired projects to enhance operational efficiency and risk control[58]. - The company established a subsidiary, Guangxi Qinkang, with a registered capital of RMB 150 million to enhance its pharmaceutical wholesale and retail operations in Guangxi[59]. - The company plans to continue expanding its business and enhancing operational efficiency through new strategies and product offerings[24].